A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

• ClinicalTrials.gov Identifier: NCT03811652
• Recruitment Status: Completed
• First Posted: January 22, 2019
• Last Update Posted: December 30, 2019
• Sponsor: MedImmune LLC
• Information provided by (Responsible Party): MedImmune LLC

Study Description

Brief Summary:

To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.

Condition or disease	Intervention/treatment	Phase
Non Small Cell Lung Cancer Squamous (NSCLC-Sq); Head and Neck Squamous Cell Carcinoma (HNSCC); Small Cell Lung Cancer (SCLC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC); Metastatic Castration-resistant Prostate Cancer (mCRPC)	Drug: MEDI7247	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 8 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors
• Actual Study Start Date: December 20, 2018
• Actual Primary Completion Date: December 10, 2019
• Actual Study Completion Date: December 10, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: NSCLC-Sq/HNSCC; Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.	Drug: MEDI7247; Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
Experimental: Small Cell Lung Cancer; Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen.	Drug: MEDI7247; Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
Experimental: Colorectal Cancer; Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available.	Drug: MEDI7247; Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
Experimental: Pancreatic Ductal Adenocarcinoma; Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment.	Drug: MEDI7247; Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
Experimental: Metastatic Castration-Resistant Prostate Cancer; Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.	Drug: MEDI7247; Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
Experimental: Other advanced/metastatic target expressing solid tumors; Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies	Drug: MEDI7247; Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Outcome Measures

Primary Outcome Measures :

1. Occurrence of Adverse Events [ Time Frame: From time of informed consent through 90 days post end of treatment ]
   To assess the occurrence of adverse events
2. Occurrence of Serious Adverse Events [ Time Frame: From time of informed consent through 90 days post end of treatment ]
   To assess the occurrence of serious adverse events
3. Occurrence of Dose Limiting Toxicities [ Time Frame: During the evaluation period of 21 days post first dose ]
   To assess the occurrence of toxicities and abnormal laboratory results that may limit further dose administration
4. Number of patients with changes in laboratory parameters from baseline [ Time Frame: From time of informed consent through 90 days post end of treatment ]
   To assess serum chemistry, hematology, urinalysis and coagulation parameters
5. Number of patients with changes in vital signs parameters from baseline [ Time Frame: from time of informed consent through 21 days post last dose ]
   to assess changes in vital signs
6. Number of patients with changes in electrocardiogram results from baseline [ Time Frame: from time of informed consent through 21 days post last dose ]
   to assess changes in ECG
7. Percentage of patients with changes in laboratory parameters from baseline [ Time Frame: from time of informed consent through 90 days post end of treatment ]
   to assess changes in serum chemistry, hematology, urinalysis, and coagulation parameters

Secondary Outcome Measures :

1. MEDI7247 maximum observed concentration (Cmax) [ Time Frame: From first dose through 90 days post end of treatment ]
   To characterize MEDI7247 single agent Pharmacokinetics
2. MEDI7247 terminal half life (t1/2) [ Time Frame: From first dose through 90 days post end of treatment ]
   To characterize single agent MEDI7247 pharmacokinetics
3. MEDI7247 area under the concentration/time curve (AUC) [ Time Frame: from first dose through 90 days post end of treatment ]
   To characterize single agent MEDI7247 pharmacokinetics
4. MEDI7247 clearance [ Time Frame: from first dose through 90 days post end of treatment ]
   to characterize the single agent MEDI7247 pharmacokinetics
5. Number of subjects who develop anti-drug antibodies [ Time Frame: first dose through 90 days post end of treatment ]
   To characterize MEDI7247 immunogenicity
6. Best Overall Response [ Time Frame: From time of informed consent and up to 90 days post end of treatment ]
   To assess antitumor activity of MEDI7247
7. Objective Response Rate (ORR) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
   To assess antitumor activity of MEDI7247
8. Time to Response (TTR) [ Time Frame: From time of informed consent and up to 90 days post end of treatment ]
   To assess antitumor activity of MEDI7247
9. Duration of Response (DoR) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
   To assess antitumor activity of MEDI7247
10. Progression Free Survival (PFS) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
    To assess the antitumor activity of MEDI7247
11. Disease Control (DC) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
    To assess antitumor activity of MEDI7247
12. Overall Survival (OS) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
    To assess antitumor activity of MEDI7247

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 101 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Confirmed diagnosis of advanced or metastatic select solid tumors and either progression on or documented intolerance to standard therapies
2. Age ≥ 18 years at the time of screening.
3. Written informed consent and any locally required authorization
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
5. At least 1 measurable target lesion by CT or MRI per RECIST Version 1.1 (excluding mCRPC)
6. Adequate Liver Function: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 × ULN (upper limit normal), Albumin > 3 g/dL, and serum total bilirubin (TBL) ≤ 1.5 × ULN; (unless bilirubin rise is due to Gilbert's syndrome, hepatic metastases or of non-hepatic origin, in which case TBL ≤ 3 × ULN is allowed)
7. Creatinine Clearance (CrCL) ≥ 40 mL/min
8. Adequate Hematopoesis: Absolute Neutrophil Count (ANC) ≥ 1,500/μL, Platelets ≥ 100,000/μL, and Hgb ≥ 9 g/dL unassisted by transfusion or growth factor within 14 days of screening
9. Provision of archival or fresh tumor tissue at screening
10. Female patients of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception, and must agree to continue using such precautions for 90 days after the last dose of investigational product.
11. Nonsterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from 7 days post-screening and for 90 days after receipt of the last dose of investigational product.

Exclusion Criteria:

1. Active central nervous system (CNS) metastases, unless adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) and prednisolone 10 mg or less for more than 2 weeks prior to enrollment. For SCLC, a brain MRI scan that was conducted ≤ 28 days from Day 1 is required.
2. Residual toxicity from prior anticancer therapy not resolved to NCI CTCAE v4.03 Grade 1, with the exception of alopecia/vitiligo at the time of first dose of investigational product. For patients previously receiving immunotherapy, toxicities that are unlikely to recover to Grade 1.
3. Royal Marsden Hospital (RMH) prognostic score 2 and 3 at baseline.
4. Treatment with anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 21 days, or prior palliative radiotherapy within 2 weeks of the first dose of investigational product.

5 Prior treatment with other Pyrrolobenzodiazepine-Antibody Drug Conjugates.

6 History of previous malignancies (except for locally curable cancers) unless a complete remission was achieved at least 3 years prior to study entry AND no additional therapy is required during the study period (except adjuvant hormonal therapy and bisphosphonate).

7. Failure to recover from major surgery or significant traumatic injury within 21 days of first dose of study treatment.

8 History of hepatic sinusoidal obstruction syndrome, also called veno-occlusive disease 9. History of capillary leak syndrome. 10 Blood transfusion within 14 days of study entry except when needed for disease related anemia.

11. New York Heart Association classes III-IV congestive heart failure or serious cardiac arrhythmia requiring treatment, history of myocardial infarction, unstable angina, vascular stent, or coronary artery bypass graft within 6 months of the first dose of investigational product. 12. Active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections at the time of screening.

13. Current severe active systemic disease including active concurrent malignancy 14. Pregnancy and/or breastfeeding at time of screening 15. Concurrent enrollment in anther clinical study involving an investigational treatment that is not an extension of another MedImmune study with the same investigational product.

Contacts and Locations

Locations

United States, North Carolina

Research Site

Huntersville, North Carolina, United States, 28078

United States, Tennessee

Research Site

Nashville, Tennessee, United States, 37203

Canada, Ontario

Research Site

Toronto, Ontario, Canada, M5G 2M9

Sponsors and Collaborators

MedImmune LLC

More Information

• Responsible Party: MedImmune LLC
• ClinicalTrials.gov Identifier: NCT03811652
• Other Study ID Numbers: D8540C00002
• First Posted: January 22, 2019
• Last Update Posted: December 30, 2019
• Last Verified: December 2019

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by MedImmune LLC:

Medi7247; non small cell lung cancer; head and neck cancer; small cell lung cancer; colorectal cancer; prostate cancer; pancreatic adenocarcinoma

Additional relevant MeSH terms:

Lung Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Adenocarcinoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male; Prostatic Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial